Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Fig. 4

Clinical outcome of ONC201-treated patients. a Swimmer plot of ONC201-treated patients showing progression-free survival, as defined by RECIST version 1.1. Each bar represents one patient on the study who has been treated on a weekly schedule with ONC201. Arrowhead indicates that the patient was still on treatment at the time of writing this manuscript. b Primary tumor and bone metastasis measurements from a patient with prostate cancer at baseline and after two doses of weekly 625 mg ONC201

Back to article page